CliffBio
biologic

Cuvitru

Immune Globulin Subcutaneous (Human), 20% Solution

Loss of exclusivitySeptember 2028projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameCuvitru
Active ingredientImmune Globulin Subcutaneous (Human), 20% Solution
Strength8G/40ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2016
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Cuvitru patent cliff — loss of exclusivity September 2028 | CliffBio